The global pharyngeal cancer therapeutics market size will grow by USD 761.06 million during 2019-2023. This market report provides a detailed analysis of the market by product (targeted therapy and chemotherapy) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Key Insights on Pharyngeal Cancer Therapeutics Market - Global Forecast 2019-2023
Browse TOC and LoE with selected illustrations and example pages of Pharyngeal Cancer Therapeutics Market
Industry Overview
Market vendors are focusing on the development of novel therapeutics with limited side effects to fulfill the vast unmet need for approved targeted therapy drugs for the treatment of pharyngeal cancer. For instance, TECENTRIQ (atezolizumab), a PD-L1 monoclonal antibody developed by Roche, is being tested in patients with adjuvant SCCHN to prevent cancer immune evasion. Similarly, Merck is developing BAVENCIO (avelumab), an anti-PD-L1 molecule for the treatment of locally advanced SCCHN. AstraZeneca is also conducting clinical trials of durvalumab, a PD-L1 molecule in combination with different drugs. The expected approvals of these late-stage molecules will fuel the growth of the pharyngeal cancer therapeutics market during the next five years.
The pharyngeal cancer therapeutics market forecast highlights the presence of high-risk factors for the disease as another factor driving market growth. Some of the significant risk factors for pharyngeal cancer include the extended use of tobacco, excessive alcohol consumption, increasing viral infections, and occupational hazards. Tobacco smoke contains carcinogens that can damage DNA and develop unusual cells leading to cancer. Alcohol abuse and its combination with tobacco further increase the risk of developing pharyngeal cancer. Also, individuals exposed to certain chemicals, dust, and fumes in their working environments, such as high-dose radiation environments and wood, metal, leather, textile, and petroleum industries have high chances of developing pharyngeal cancer. Such factors are expected to increase the prevalence of pharyngeal cancer and consequently boost the growth of the pharyngeal cancer therapeutics market at a CAGR of over 6% during the forecast period.
Top Companies in Pharyngeal Cancer Therapeutics Market
The global market is fragmented. To help clients improve their market position, this report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this pharyngeal cancer therapeutics market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the future growth opportunities.
The report offers a detailed analysis of several leading pharyngeal cancer therapeutics companies, including:
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Mylan NV
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
Market Segmentation
Pharyngeal Cancer Therapeutics Market by Product
- Targeted therapy
- Chemotherapy
The targeted therapy segment will account for the highest pharyngeal cancer therapeutics market share. The expected approval of late-stage molecules and the development of novel targeted therapies are some of the factors driving the growth of the pharyngeal cancer therapeutics market in this segment. This market research report provides an accurate prediction of the contribution of all the segments to the growth of the pharyngeal cancer therapeutics market size.
Pharyngeal Cancer Therapeutics Market by Region
- Asia
- Europe
- North America
- ROW
With a complete study of the growth opportunities for companies, it has been identified that North America will account for the highest share of the pharyngeal cancer therapeutics market throughout the forecast period. The high prevalence of pharyngeal cancer and recent product approvals are contributing to the pharyngeal cancer therapeutics market growth in this region.
Major Highlights of the Pharyngeal Cancer Therapeutics Market - Global Forecast 2019-2023
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the pharyngeal cancer therapeutics market during the next five years
- Precise estimation of the global pharyngeal cancer therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the pharyngeal cancer therapeutics industry across Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details of factors that will challenge the growth of pharyngeal cancer therapeutics companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch